Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Skin Neoplasms × Tomography, Optical Coherence × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Basal Cell 3 Pancreatic Neoplasms 2 Urinary Bladder Neoplasms 1 Telangiectasis 1 Skin Neoplasms 1 Rosacea 1 Prostatic Neoplasms 1 Precancerous Conditions 1 Port-Wine Stain 1 Pancreatic Intraductal Neoplasms 1 Non-melanoma Skin Cancer 1 Nevus, Pigmented 1 Mixed Tumor, Malignant 1 Melanoma 1 Lung Neoplasms 1 Keratosis, Seborrheic 1 Keratosis 1 Hemangioma 1 Glioma 1 Carcinoma, Transitional Cell 1 Carcinoma 1 Barrett Esophagus 1

Interventions

pembrolizumab 19 aldesleukin 19 Nivolumab 19 Cyclophosphamide 18 Ipilimumab 16 fludarabine 14 Interleukin-2 14 fludarabine phosphate 12 cemiplimab 11 Radiotherapy 7 Fluorouracil 6 Dacarbazine 6 Vemurafenib 5 Radiation 5 Biopsy 5 Aminolevulinic Acid 5 dabrafenib 4 binimetinib 4 Temozolomide 4 Surgical Procedures, Operative 4 Sirolimus 4 Educational Status 4 trametinib 3 sonidegib 3 montanide ISA 51 3 encorafenib 3 avelumab 3 Sodium Chloride 3 Semaxinib 3 Photochemotherapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01662713 2023-03-15

OFDI

Massachusetts General Hospital

Phase NA Completed

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡